• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    69 Biggest Movers From Yesterday

    6/6/22 5:31:12 AM ET
    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ACOR alert in real time by email

    Gainers

    • Turning Point Therapeutics, Inc. (NASDAQ:TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.
    • Energy Focus, Inc. (NASDAQ:EFOI) shares gained 48.7% to settle at $1.65 after declining around 9% on Thursday.
    • Galecto, Inc. (NASDAQ:GLTO) jumped 35.2% to settle at $1.96.
    • Yumanity Therapeutics, Inc. (NASDAQ:YMTX) gained 34% to close at $1.42. Yumanity Therapeutics, last month, posted a Q1 loss of $1.24 per share.
    • Houston American Energy Corp. (NYSE:HUSA) climbed 27.5% to close at $5.65.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) climbed 26.4% to close at $12.35 after the company announced the FDA extended the review timeline of the New Drug Application for AMX0035.
    • Forian Inc. (NASDAQ:FORA) gained 24.2% to close at $4.05. Forian, last month, posted a Q1 loss of $0.37 per share.
    • Integrated Media Technology Limited (NASDAQ:IMTE) jumped 22.9% to settle at $12.19.
    • Eros STX Global Corporation (NYSE:ESGC) gained 22.2% to settle at $3.03.
    • Harpoon Therapeutics, Inc. (NASDAQ:HARP) climbed 21.2% to close at $2.40.
    • AudioEye, Inc. (NASDAQ:AEYE) jumped 20.8% to close at $4.07. AudioEye's board approved a share buyback of up to $3 million, expiring on June 30, 2024.
    • Global Cord Blood Corporation (NYSE:CO) gained 20.6% to close at $3.46.
    • GreenBox POS (NASDAQ:GBOX) rose 20.3% to settle at $2.55.
    • Predictive Oncology Inc. (NASDAQ:POAI) jumped 21.1% to close at $0.46.
    • Accelerate Diagnostics, Inc. (NASDAQ:AXDX) gained 20.1% to close at $0.7210. Accelerate Diagnostics, last month, posted a Q1 loss of $0.25 per share.
    • Cortexyme, Inc. (NASDAQ:CRTX) gained 20.1% to settle at $3.17.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) jumped 20% to close at $1.11.
    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) gained 19.8% to settle at $0.3725.
    • The Marygold Companies, Inc. (NYSE:MGLD) rose 19.7% to close at $1.76. Marygold Companies, last month, posted Q1 earnings of $0.02 per share.
    • Sprague Resources LP (NYSE:SRLP) shares climbed 19.6% to close at $18.93 after the company announced an agreement to be acquired by Hartree Partners for $19 per common unit.
    • Spark Networks SE (NASDAQ:LOV) gained 19.5% to close at $3.37.
    • IsoPlexis Corporation (NASDAQ:ISO) jumped 19.1% to settle at $2.56.
    • Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) climbed 18.9% to settle at $7.85. Iovance Biotherapeutics Director Wayne P Rothbaum acquired a total of 1,000,000 shares at at an average price of $6.60.
    • Wave Life Sciences Ltd. (NASDAQ:WVE) gained 18.8% to close at $1.58.
    • Puma Biotechnology, Inc. (NASDAQ:PBYI) gained 18.2% to close at $2.34. Puma Biotechnology presented final results from the biliary tract cohort of the Phase 2 SUMMIT basket trial of neratinib at ASCO.
    • CuriosityStream Inc. (NASDAQ:CURI) jumped 17.8% to close at $1.79.
    • Atento S.A. (NYSE:ATTO) gained 17.7% to close at $13.03. Atento announced cooperation agreement with investors.
    • Homology Medicines, Inc. (NASDAQ:FIXX) rose 17.3% to settle at $1.76. Homology Medicines recently received FDA orphan drug approval for recombinant adeno-associated viral vector serotype HSC15 for treatment of phenylalanine hydroxylase deficiency.
    • Precision BioSciences, Inc. (NASDAQ:DTIL) gained 17% to close at $1.79.
    • Adaptimmune Therapeutics plc (NASDAQ:ADAP) jumped 16.8% to close at $1.67.
    • Nine Energy Service, Inc. (NYSE:NINE) gained 16.7% to close at $3.92.
    • Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) rose 16.4% to close at $2.27.
    • Nurix Therapeutics, Inc. (NASDAQ:NRIX) climbed 16.3% to close at $10.57. Nurix Therapeutics will present trial in progress posters for three clinical programs Jun. 4 and 5.
    • Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) gained 16.3% to settle at $3.36.
    • Jowell Global Ltd. (NASDAQ:JWEL) gained 16.1% to close at $3.25. Jowell Global recently posted Q1 sales of $45.10 million.
    • Evofem Biosciences, Inc. (NASDAQ:EVFM) climbed 15.8% to settle at $0.3980.
    • RCM Technologies, Inc. (NASDAQ:RCMT) gained 15.7% to close at $28.00.
    • Pear Therapeutics, Inc. (NASDAQ:PEAR) rose 14.8% to close at $4.34.
    • Calavo Growers, Inc. (NASDAQ:CVGW) gained 14% to close at $37.84 following better-than-expected Q2 results.
    • StoneCo Ltd. (NASDAQ:STNE) rose 13.2% to close at $11.80 after the company reported first-quarter revenue growth of 138.6% year-over-year to R$2.07 billion, above the mid-range of the company’s guidance of R$1.85 billion and R$1.9 billion.
    • Boqii Holding Limited (NYSE:BQ) gained 11% to close at $2.1704.
    • Society Pass Incorporated (NASDAQ:SOPA) gained 11% to close at $2.32 after the company announced it acquired Gorilla Networks.
    • Quanex Building Products Corporation (NYSE:NX) climbed 10.5% to close at $22.91 after the company reported better-than-expected Q2 results and issued FY22 sales guidance above estimates.
    • Mirati Therapeutics, Inc. (NASDAQ:MRTX) rose 10.1% to close at $44.33.
    • Kubient, Inc. (NASDAQ:KBNT) rose 8.5% to close at $1.08.
    • Okta, Inc. (NASDAQ:OKTA) rose 5% to close at $98.38 after the company reported better-than-expected Q1 sales results. The company also issued Q2 sales guidance above analyst estimates.

     

     

    Losers

    • Bit Origin Limited (NASDAQ:BTOG) shares dropped 44.4% to close at $0.4780 on Friday as the company reported a proposed underwritten public offering of ordinary shares.
    • TC Biopharm (Holdings) Plc (NASDAQ:TCBP) shares dipped 36.1% to close at $0.3850 after the company reported pricing of $4 million underwritten public offering.
    • Rallybio Corporation (NASDAQ:RLYB) dropped 30% to close at $9.26. Rallybio announced that Jeffrey Fryer, CPA, will retire from his position as Chief Financial Officer.
    • Zosano Pharma Corporation (NASDAQ:ZSAN) dropped 22% to close at $0.78. Zosano Pharma recently announced it filed a voluntary petition for relief under chapter 11.
    • NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) fell 20.4% to settle at $1.09.
    • Novavax, Inc. (NASDAQ:NVAX) fell 20% to close at $44.76. The U.S. FDA published briefing documents on Novavax Covid-19 vaccine for individuals aged 18 and older.
    • JOANN Inc. (NASDAQ:JOAN) dropped 19.5% to close at $6.36 after the company said Q1 EPS results were lower year over year and reported worse-than-expected Q1 sales results.
    • Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) fell 19.2% to close at $1.18.
    • HashiCorp, Inc. (NASDAQ:HCP) shares fell 17.6% to close at $34.00 after the company reported Q1 earnings results and issued guidance.
    • Grom Social Enterprises, Inc. (NASDAQ:GROM) dipped 15.7% to close at $0.5901.
    • Bright Green Corporation (NASDAQ:BGXX) dropped 15.6% to close at $3.04.
    • Invitae Corporation (NYSE:NVTA) dipped 15.2% to settle at $3.02. Piper Sandler initiated coverage on Invitae with an Underweight rating and announced a price target of $2.5.
    • Fast Radius, Inc. (NASDAQ:FSRD) fell 15.1% to settle at $0.45.
    • Mercurity Fintech Holding Inc. (NASDAQ:MFH) dipped 14.6% to close at $1.05.
    • Dave Inc. (NASDAQ:DAVE) dropped 13.5% to close at $1.99.
    • NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) fell 12.9% to close at $0.7345.
    • Gravitas Education Holdings, Inc. (NYSE:GEHI) fell 11% to close at $0.62.
    • Acorda Therapeutics, Inc. (NASDAQ:ACOR) fell 10% to close at $0.30.
    • Context Therapeutics Inc. (NASDAQ:CNTX) fell 8.7% to close at $2.00.
    • Wayfair Inc. (NYSE:W) dipped 8.6% to close at $58.30.
    • Zumiez Inc. (NASDAQ:ZUMZ) fell 8.8% to settle at $31.16 after the company reported worse-than-expected Q1 EPS results and issued Q2 EPS and sales guidance below analyst estimates.
    • Impac Mortgage Holdings, Inc. (NYSE:IMH) fell 6.7% to close at $0.7702.
    • Talkspace, Inc. (NASDAQ:TALK) fell 6.3% to close at $1.65 after jumping 34% on Thursday.
    Get the next $ACOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOR
    $ADAP
    $AEYE
    $AMLX

    CompanyDatePrice TargetRatingAnalyst
    Wave Life Sciences Ltd.
    $WVE
    2/5/2026$38.00Buy
    BofA Securities
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Okta Inc.
    $OKTA
    1/14/2026$120.00Equal-Weight → Overweight
    Stephens
    Nurix Therapeutics Inc.
    $NRIX
    1/8/2026$36.00Equal-Weight → Overweight
    Morgan Stanley
    Olema Pharmaceuticals Inc.
    $OLMA
    1/7/2026$40.00Overweight
    Piper Sandler
    Wayfair Inc.
    $W
    1/7/2026$123.00Equal Weight → Overweight
    Barclays
    Galecto Inc.
    $GLTO
    1/7/2026$46.00Outperform
    Leerink Partners
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    More analyst ratings

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hendricks John S

    4 - CuriosityStream Inc. (0001776909) (Issuer)

    2/6/26 1:15:45 PM ET
    $CURI
    Movies/Entertainment
    Consumer Discretionary

    Director Hendricks Elizabeth Ann converted options into 38,500 shares, increasing direct ownership by 29% to 172,785 units (SEC Form 4)

    4 - CuriosityStream Inc. (0001776909) (Issuer)

    2/6/26 12:51:06 PM ET
    $CURI
    Movies/Entertainment
    Consumer Discretionary

    Director Nikzad Michael converted options into 38,500 shares, increasing direct ownership by 24% to 196,000 units (SEC Form 4)

    4 - CuriosityStream Inc. (0001776909) (Issuer)

    2/6/26 12:41:49 PM ET
    $CURI
    Movies/Entertainment
    Consumer Discretionary

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Nine Energy Service Inc.

    SCHEDULE 13G/A - Nine Energy Service, Inc. (0001532286) (Subject)

    2/6/26 5:54:44 PM ET
    $NINE
    Oilfield Services/Equipment
    Energy

    Amendment: SEC Form S-1/A filed by Society Pass Incorporated

    S-1/A - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    2/6/26 5:26:07 PM ET
    $SOPA
    Real Estate

    Society Pass Incorporated filed SEC Form 8-K: Other Events

    8-K - SOCIETY PASS INCORPORATED. (0001817511) (Filer)

    2/6/26 5:00:27 PM ET
    $SOPA
    Real Estate

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    August 30, 2024 - La FDA autoriza la vacuna contra el COVID-19 de Novavax actualizada para brindar una mejor protección contra las variantes que circulan actualmente.

    For Immediate Release: August 30, 2024 English Hoy, la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA, por sus siglas en inglés) otorgó una autorización de uso de emergencia (EUA, por sus siglas en inglés) para una versión actualizada de la vacuna contra el COVID-19 de Novavax que ataca más de cerca a las variantes que circulan actualmente para brindar una mejor protección contra las cons

    9/3/24 2:26:49 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    August 30, 2024 - FDA Authorizes Updated Novavax COVID-19 Vaccine to Better Protect Against Currently Circulating Variants

    For Immediate Release: August 30, 2024 Today, the U.S. Food and Drug Administration granted emergency use authorization (EUA) for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalization and death. The updated vaccine is authorized for use in individuals 12 years of

    8/30/24 2:26:48 PM ET
    $NVAX
    $PFE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    February 16, 2024 - FDA Approves First Cellular Therapy to Treat Patients with Unresectable or Metastatic Melanoma

    For Immediate Release: February 16, 2024 Today, the U.S. Food and Drug Administration approved Amtagvi, the first cellular therapy indicated for the treatment of adult patients with a type of skin cancer (melanoma) that is unable to be removed with surgery (unresectable) or has spread to other parts of the body (metastatic) that previously has been treated with other therapies (a PD-1 blocking antibody, and if B

    2/16/24 3:48:47 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Best-in-Class Real-World Data Support Early Amtagvi® Treatment in Advanced Melanoma

    SAN CARLOS, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced data demonstrating a best-in-class profile for commercial Amtagvi® (lifileucel) with unprecedented response rates in a real-world clinical, retrospective study in patients with advanced (unresectable or metastatic) melanoma. Amtagvi is the first one-time T cell therapy for a solid tumor cancer as well as the only FDA-approved treatment for advanced melanoma patients previously treated with anti-PD-1 and ta

    2/5/26 5:15:00 PM ET
    $IOVA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    The Marygold Companies Reports Financial Results For its Second Fiscal Quarter Ended December 31, 2025

    The Marygold Companies, Inc. (the "Company") (NYSE:MGLD), a global holding firm with a focus on financial services, today reported financial results for its second fiscal quarter ended December 31, 2025. Revenue for the three months ended December 31, 2025, amounted to $7.6 million, compared with the prior year period, when revenues were $8.0 million and which also included $0.6 million from Brigadier Security Systems (2000) Ltd. ("Brigadier"), a wholly owned subsidiary that was sold in July 2025 for $2.5 million. The Company's net loss for the quarter was $0.6 million as compared with a net loss of $1.7 million for the second quarter of the prior fiscal year. The $1.1 million improvement

    2/5/26 5:00:00 PM ET
    $MGLD
    Finance: Consumer Services
    Finance

    Dave Reports Preliminary Fourth Quarter and Full Year 2025 Results

    2025 Revenue and Adjusted EBITDA Results are Expected to Exceed the Top-End of Guidance 4Q25 28 DPD Rate Expected to be Within the Range of 1.95%-2.00%, Outperforming Guidance of Below 2.10% Full Earnings Results and 2026 Financial Outlook to Be Discussed on March 2, 2026 at 5:00pm ET LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company expects to release full, audited financial results and file its annual report on Form 10-K for the year ended December 31, 2025 on Mar

    2/5/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Huang Chiao Chieh bought $600,001 worth of shares (262,009 units at $2.29), increasing direct ownership by 23% to 1,421,219 units (SEC Form 4)

    4 - ENERGY FOCUS, INC/DE (0000924168) (Issuer)

    12/31/25 9:21:21 AM ET
    $EFOI
    Building Products
    Consumer Discretionary

    Director Firestone Karen bought $100,845 worth of shares (8,100 units at $12.45), increasing direct ownership by 15% to 63,100 units (SEC Form 4)

    4 - Amylyx Pharmaceuticals, Inc. (0001658551) (Issuer)

    12/23/25 8:48:33 PM ET
    $AMLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Germano Geno J bought $14,160 worth of shares (3,000 units at $4.72), increasing direct ownership by 14% to 23,883 units (SEC Form 4)

    4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)

    12/17/25 7:02:05 AM ET
    $DTIL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BofA Securities initiated coverage on Wave Life Sciences with a new price target

    BofA Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $38.00

    2/5/26 9:31:24 AM ET
    $WVE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Avalo Therapeutics with a new price target

    Guggenheim initiated coverage of Avalo Therapeutics with a rating of Buy and set a new price target of $50.00

    2/2/26 6:51:00 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Okta upgraded by Stephens with a new price target

    Stephens upgraded Okta from Equal-Weight to Overweight and set a new price target of $120.00

    1/14/26 8:22:37 AM ET
    $OKTA
    Computer Software: Prepackaged Software
    Technology

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Leadership Updates

    Live Leadership Updates

    View All

    Dave Inc. Appoints Nima Khajehnouri to Board of Directors; Announces Board Leadership Transitions

    LOS ANGELES, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced that Nima Khajehnouri, a distinguished leader in artificial intelligence and data engineering, has joined its Board of Directors, effective immediately. Mr. Khajehnouri will serve as a member of the Company's Audit Committee. Imran Khan, who has served on the Board since August 2023, is stepping down in conjunction with this appointment. Mr. Khajehnouri brings more than two decades' experience of leading engineering at some of the world's most influential technology companies. He currently serves as Vice President of Engineering at Meta, h

    1/20/26 5:27:46 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

    DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an

    1/12/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    StoneCo Announces New CEO, Reinforcing Continuity and Execution

    George Town, Grand Cayman--(Newsfile Corp. - January 7, 2026) - StoneCo Ltd. (NASDAQ:STNE) ("Stone" or "the Company") announces today that Mr. Pedro Zinner has informed the Board of Directors of his decision to resign from his position as Chief Executive Officer, effective March 2026, for personal reasons.Mr. Zinner assumed the role of CEO three years ago, following his service on the Company's Board, at a critical moment in Stone's trajectory. During his tenure, Stone executed a clear strategic pivot, including the divestment of non-core assets such as Linx, the implementation of broad streamlining initiatives, the establishment of a disciplined capital allocation framework, and meaningful

    1/7/26 7:10:00 AM ET
    $STNE
    EDP Services
    Technology

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Financials

    Live finance-specific insights

    View All

    The Marygold Companies Reports Financial Results For its Second Fiscal Quarter Ended December 31, 2025

    The Marygold Companies, Inc. (the "Company") (NYSE:MGLD), a global holding firm with a focus on financial services, today reported financial results for its second fiscal quarter ended December 31, 2025. Revenue for the three months ended December 31, 2025, amounted to $7.6 million, compared with the prior year period, when revenues were $8.0 million and which also included $0.6 million from Brigadier Security Systems (2000) Ltd. ("Brigadier"), a wholly owned subsidiary that was sold in July 2025 for $2.5 million. The Company's net loss for the quarter was $0.6 million as compared with a net loss of $1.7 million for the second quarter of the prior fiscal year. The $1.1 million improvement

    2/5/26 5:00:00 PM ET
    $MGLD
    Finance: Consumer Services
    Finance

    Dave Reports Preliminary Fourth Quarter and Full Year 2025 Results

    2025 Revenue and Adjusted EBITDA Results are Expected to Exceed the Top-End of Guidance 4Q25 28 DPD Rate Expected to be Within the Range of 1.95%-2.00%, Outperforming Guidance of Below 2.10% Full Earnings Results and 2026 Financial Outlook to Be Discussed on March 2, 2026 at 5:00pm ET LOS ANGELES, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dave Inc. ("Dave" or the "Company") (NASDAQ:DAVE), one of the nation's leading neobanks, today announced certain preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company expects to release full, audited financial results and file its annual report on Form 10-K for the year ended December 31, 2025 on Mar

    2/5/26 4:15:00 PM ET
    $DAVE
    Finance: Consumer Services
    Finance

    Talkspace to Report Fourth Quarter and Full Year 2025 Results and Host Conference Call

    NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Talkspace (NASDAQ:TALK),  a leading behavioral healthcare company, today announced that it will release its fourth quarter and full year 2025 results on Thursday, February 19, 2026 before market open and host a conference call to review the results at 8:30am ET. Conference Call DetailsThe conference call will be available via audio webcast at https://investors.talkspace.com/ and can also be accessed by dialing (800) 225-9448 for U.S. participants, or (203) 518-9708 for international participants, and using conference ID TALKQ425. A replay will be available shortly after the call's completion and remain available for approximately 90 days. About

    2/5/26 4:05:00 PM ET
    $TALK
    Medical/Nursing Services
    Health Care

    $ACOR
    $ADAP
    $AEYE
    $AMLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Olema Pharmaceuticals Inc.

    SC 13G - Olema Pharmaceuticals, Inc. (0001750284) (Subject)

    12/11/24 4:30:15 PM ET
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verrica Pharmaceuticals Inc.

    SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)

    12/9/24 6:22:49 PM ET
    $VRCA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Accelerate Diagnostics Inc.

    SC 13D/A - Accelerate Diagnostics, Inc (0000727207) (Subject)

    12/5/24 5:13:13 PM ET
    $AXDX
    Biotechnology: Laboratory Analytical Instruments
    Industrials